EW
GCVRZ

Evoke Wealth’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Evoke Wealth’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-237
Closed -$132 – 1562
2019
Q3 		$132 Buy
+237
New +$127 ﹤0.01% 1396

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Evoke Wealth's GCVRZ Position: Q4 2019 in Review

Evoke Wealth sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2019, closing a stake of 237 shares — an estimated $132 sold.

Evoke Wealth first reported a position in GCVRZ in Q3 2019 and held it in 1 quarter. The position peaked at $132 in Q3 2019. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2019.

  • Evoke Wealth reported no remaining Sanofi Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
  • Evoke Wealth sold 237 Sanofi Contingent Value Rights shares in Q4 2019, an estimated $132.
  • Evoke Wealth first reported a position in Sanofi Contingent Value Rights in Q3 2019 and held it in 1 quarter.
  • Evoke Wealth's Sanofi Contingent Value Rights position peaked at $132 in Q3 2019.
  • 103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2019.

Based on Evoke Wealth's 13F filing for Q4 2019, filed 7 Feb 2020.